In December, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider an application from Novartis for Everolimus/Afinitor to be listed on the Pharmaceutical Benefits Scheme (PBS) for people with TSC who are experiencing seizures that do not respond well to available treatments.
If the medicine is approved for listing it will be funded by the Australian government as a part of the PBS.
Tuberous Sclerosis Australia will make a submission on behalf of our members and the wider Australian TSC community. Thank you to everyone who has helped Anna and Clare with this submission already.
In addition to TSA’s submission, it is possible for individuals with TSC or their family members to make their own submission. We encourage you to do this.
Link to PBAC Consumer Comments form
For more information about these medicines, please read our mTOR inhibitor information page. Please contact us if you would like any help with this or to find out more about these medicines.
Leave a Reply
You must be logged in to post a comment.